Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ready Mixed Concrete01:26

Ready Mixed Concrete

373
Ready-mixed concrete, also known as pre-mixed concrete, is prepared in a centralized plant and then transported in trucks to construction sites where it is ready for placement. This type of concrete is categorized into central-mixed, truck-mixed (or transit-mixed), and shrink-mixed. Central-mixed concrete is entirely prepared at a plant and moved to the site in agitator trucks that rotate at a speed of 2 to 6 rpm. Truck-mixed concrete, on the other hand, has the ingredients batched at the plant...
373
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

279
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
279
Egoism and Altruism01:55

Egoism and Altruism

93.4K
Voluntary behavior with the intent to help other people is called prosocial behavior. Why do people help other people? Is personal benefit such as feeling good about oneself the only reason people help one another?
93.4K
The Born-Haber Cycle02:44

The Born-Haber Cycle

25.5K
Lattice Energy 
25.5K
First Law of Thermodynamics02:16

First Law of Thermodynamics

41.1K
Energy Conservation
41.1K
Measuring Reaction Rates03:09

Measuring Reaction Rates

30.3K
Polarimetry finds application in chemical kinetics to measure the concentration and reaction kinetics of optically active substances during a chemical reaction. Optically active substances have the capability of rotating the plane of polarization of linearly polarized light passing through them—a feature called optical rotation. Optical activity is attributed to the molecular structure of substances. Normal monochromatic light is unpolarized and possesses oscillations of the electrical...
30.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors Associated With Pancreatectomy Among Australians With Pancreatic Cancer: A Population-Based Study.

ANZ journal of surgery·2026
Same author

Stakeholder Consensus Selection of Data Elements and Indicators for a Pancreatic Cancer Surgical Outcomes Registry in Australia and Aotearoa New Zealand: Modified Delphi Process.

ANZ journal of surgery·2026
Same author

The Association Between Health-Related Quality of Life Scores and Clinical Outcomes for People Living With Lung Cancer: An Australian Registry Cohort Study Using Patient-Reported Outcomes to Drive Value-Based Healthcare.

Thoracic cancer·2026
Same author

Quality Matters: Linking Patterns of Care to Ovarian Cancer Survival in a National Gynae-Oncology Registry.

JCO oncology practice·2026
Same author

Utilization of Lung Cancer Registries in Learning Health Systems for Health Care Improvement.

JCO clinical cancer informatics·2025
Same author

Barriers and Breakthroughs in Precision Oncology: A National Registry Study of <i>BRCA</i> Testing and PARP Inhibitor Uptake in Women from the National Gynae-Oncology Registry (NGOR).

Cancers·2025
Same journal

The paradox of peer review: protecting science or policing thought?

Internal medicine journal·2026
Same journal

Immune-related pancytopenia in pregnancy.

Internal medicine journal·2026
Same journal

Crossover effect: causal machine learning reveals opposing mortality responses to mean arterial pressure targets among phenotypically distinct hypertensive patients with septic shock.

Internal medicine journal·2026
Same journal

Clinicopathological findings, correlations and outcomes in patients with renal disease and living with antiretroviral-treated human immunodeficiency virus infection.

Internal medicine journal·2026
Same journal

Approach to thyroid disorders associated with immune checkpoint inhibitors and tyrosine kinase inhibitors.

Internal medicine journal·2026
Same journal

A scoping review of specialist hypertension clinics.

Internal medicine journal·2026
See all related articles

Related Experiment Video

Updated: Feb 8, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Biosimilars are coming: ready or not.

John Zalcberg1

  • 1Cancer Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

Internal Medicine Journal
|July 10, 2018
PubMed
Summary
This summary is machine-generated.

Biosimilars are impacting biologic medicine access in Australia, especially for cancer and inflammatory conditions. Further regulatory clarity and clinical trials can expand their use to new indications, benefiting patients and healthcare.

Keywords:
Australiabevacizumabbiosimilarscancertrastuzumab

More Related Videos

Ready-To-Use qPCR for Detection of DNA from Trypanosoma cruzi or Other Pathogenic Organisms
05:50

Ready-To-Use qPCR for Detection of DNA from Trypanosoma cruzi or Other Pathogenic Organisms

Published on: January 20, 2022

1.9K
Modified Most Probable Number Assay to Quantify Salmonella in Raw and Ready-to-Cook Chicken Products
08:19

Modified Most Probable Number Assay to Quantify Salmonella in Raw and Ready-to-Cook Chicken Products

Published on: January 31, 2025

1.0K

Related Experiment Videos

Last Updated: Feb 8, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Ready-To-Use qPCR for Detection of DNA from Trypanosoma cruzi or Other Pathogenic Organisms
05:50

Ready-To-Use qPCR for Detection of DNA from Trypanosoma cruzi or Other Pathogenic Organisms

Published on: January 20, 2022

1.9K
Modified Most Probable Number Assay to Quantify Salmonella in Raw and Ready-to-Cook Chicken Products
08:19

Modified Most Probable Number Assay to Quantify Salmonella in Raw and Ready-to-Cook Chicken Products

Published on: January 31, 2025

1.0K

Area of Science:

  • Pharmacoeconomics
  • Regulatory Science
  • Oncology Supportive Care

Background:

  • Biosimilars have significantly influenced biologic medicine availability in Australia, particularly for supportive oncology care and inflammatory diseases.
  • The upcoming wave of biosimilars is expected to include oncology drugs that modify disease processes, offering potential healthcare system benefits and improved patient access.

Purpose of the Study:

  • To review the concept of biosimilarity and outline the regulatory pathway for biosimilar approval in Australia.
  • To highlight the potential benefits of biosimilars for patients and the healthcare system, and explore opportunities for innovation.
  • To describe the Australian regulatory framework, including the rationale for indication extrapolation.

Main Methods:

  • Literature review of biosimilar concepts and regulatory pathways.
  • Analysis of the Australian regulatory framework for biosimilar approval.
  • Discussion of clinical characteristics and potential benefits.

Main Results:

  • Biosimilars offer potential to reduce healthcare burden and increase patient access to treatments.
  • Uncertainty exists among Australian physicians regarding regulatory pathways and clinical characteristics of biosimilars.
  • The Australian framework allows for indication extrapolation based on scientific rationale.

Conclusions:

  • Biosimilars present significant opportunities for Australia's healthcare system and patient access to medicines.
  • Further research and clinical trial collaborations can expand biosimilar applications to new disease indications.
  • Addressing physician uncertainty is key to maximizing the benefits of biosimilars.